lanreotide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
peptides and glycopeptides 1546 108736-35-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lanreotide
  • angiopeptin
  • ipstyl
  • lanreotide autogel
  • somatulin-autogel
  • somatuline
  • lanreotide acetate
synthetic octapeptide analog of somatostatin; inhibits accelerated transplant atherosclerosis in rabbit heart arteries
  • Molecular weight: 1096.33
  • Formula: C54H69N11O10S2
  • CLOGP: 3.42
  • LIPINSKI: 3
  • HAC: 21
  • HDO: 13
  • TPSA: 355.08
  • ALOGS: -5.34
  • ROTB: 17
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 mg P

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.70 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.03 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 1.070 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 3.698 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.114 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 5.200 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 9.440 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 10.580 % High 1
herg hERG pIC50 4.346 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 53.580 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 27.102 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 11.790 % High 1
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2D,CDK5,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC 16
kinase-selectivity-class AXL,GRK2 2
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 3.548 Moderate 0.74
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.143 High 1
mh-clint Mouse hepatocyte intrinsic clearance 42.267 High 1
mppb Mouse plasma protein binding (% unbound) 5.150 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.216 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 9.940 % High 1
rh-clint Rat hepatocyte intrinsic clearance 22.803 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 19.420 % High 1
rppb Rat plasma protein binding (% unbound) 4.450 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 52.240 uM High 1

Approvals:

DateAgencyCompanyOrphan
Dec. 12, 2020 PMDA TEIJIN PHARMA LIMITED
Aug. 30, 2007 FDA IPSEN PHARMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Inappropriate schedule of product administration 297.90 18.30 223 14398 149710 90464116
Injection site mass 271.22 18.30 110 14511 21980 90591846
Diarrhoea 234.66 18.30 485 14136 938705 89675121
Insulin-like growth factor increased 226.89 18.30 48 14573 926 90612900
Malignant neoplasm progression 183.71 18.30 146 14475 106724 90507102
Death 171.74 18.30 282 14339 456269 90157557
Off label use 150.11 18.30 452 14169 1101800 89512026
Abdominal pain 149.46 18.30 245 14376 395476 90218350
Injection site pain 143.88 18.30 158 14463 173541 90440285
Flatulence 120.61 18.30 78 14543 41289 90572537
Cholelithiasis 112.80 18.30 82 14539 52424 90561402
Abdominal distension 104.96 18.30 117 14504 130484 90483342
Blood growth hormone increased 100.21 18.30 22 14599 508 90613318
Flushing 82.89 18.30 86 14535 88405 90525421
Intestinal obstruction 77.50 18.30 57 14564 37074 90576752
Weight decreased 73.54 18.30 178 14443 379732 90234094
Neoplasm progression 72.56 18.30 59 14562 44427 90569399
Metastases to liver 71.14 18.30 49 14572 28758 90585068
Blood glucose increased 67.50 18.30 80 14541 95166 90518660
Disease progression 67.21 18.30 103 14518 156512 90457314
Injection site nodule 64.37 18.30 25 14596 4448 90609378
Faeces pale 63.24 18.30 20 14601 1943 90611883
Carcinoid tumour pulmonary 62.89 18.30 15 14606 505 90613321
Hepatic neoplasm 57.01 18.30 19 14602 2179 90611647
Asthenia 53.41 18.30 198 14423 533553 90080273
Tumour pain 51.70 18.30 17 14604 1870 90611956
Product dose omission issue 51.45 18.30 132 14489 291555 90322271
Rash 49.55 18.30 34 14587 796066 89817760
Blood glucose decreased 48.95 18.30 36 14585 23393 90590433
Hypoglycaemia 48.37 18.30 58 14563 69790 90544036
Genitourinary tract neoplasm 47.05 18.30 8 14613 43 90613783
Abnormal faeces 45.44 18.30 22 14599 6660 90607166
Terminal state 45.03 18.30 17 14604 2801 90611025
Nausea 43.73 18.30 317 14304 1109999 89503827
Carcinoid crisis 43.43 18.30 10 14611 288 90613538
Drug hypersensitivity 42.85 18.30 11 14610 463598 90150228
Constipation 42.50 18.30 120 14501 280275 90333551
Needle issue 42.39 18.30 27 14594 13907 90599919
Steatorrhoea 41.76 18.30 11 14610 557 90613269
Rheumatoid arthritis 41.30 18.30 5 14616 362609 90251217
Carcinoid syndrome 40.78 18.30 9 14612 213 90613613
Abdominal pain upper 40.67 18.30 132 14489 332542 90281284
Glossodynia 40.44 18.30 3 14618 321776 90292050
Treatment delayed 39.67 18.30 10 14611 425 90613401
Hot flush 38.92 18.30 48 14573 59440 90554386
Decreased appetite 38.70 18.30 141 14480 376399 90237427
Menopausal symptoms 36.63 18.30 15 14606 3063 90610763
Insulin-like growth factor abnormal 35.82 18.30 6 14615 29 90613797
Product administered at inappropriate site 35.45 18.30 16 14605 4135 90609691
Stomatitis haemorrhagic 35.19 18.30 7 14614 98 90613728
Bronchiolitis 35.13 18.30 15 14606 3397 90610429
Injection site haemorrhage 34.88 18.30 32 14589 28286 90585540
Malaise 34.70 18.30 186 14435 585800 90028026
Syncope 34.43 18.30 70 14551 132593 90481233
Hand deformity 33.95 18.30 4 14617 296358 90317468
Hospitalisation 33.73 18.30 68 14553 128032 90485794
Arthropathy 33.24 18.30 9 14612 366233 90247593
Injection site discomfort 32.86 18.30 17 14604 5923 90607903
Pericarditis 32.61 18.30 3 14618 270148 90343678
Metastases to abdominal cavity 31.74 18.30 9 14612 601 90613225
Injection site pruritus 31.35 18.30 41 14580 53793 90560033
Pelvic neoplasm 31.18 18.30 8 14613 365 90613461
Blood chromogranin A increased 30.87 18.30 8 14613 380 90613446
Salpingectomy 30.41 18.30 8 14613 403 90613423
Sinusitis 30.08 18.30 9 14612 343079 90270747
Wound 28.34 18.30 7 14614 302973 90310853
Metastases to spinal cord 28.08 18.30 7 14614 284 90613542
Gastroenteropancreatic neuroendocrine tumour disease 28.03 18.30 5 14616 37 90613789
Vomiting 27.50 18.30 219 14402 788074 89825752
Hypersensitivity 27.46 18.30 20 14601 454657 90159169
Insulinoma 27.39 18.30 6 14615 137 90613689
Drug intolerance 26.63 18.30 20 14601 447571 90166255
Treatment failure 26.59 18.30 8 14613 303920 90309906
Faeces discoloured 26.08 18.30 24 14597 21296 90592530
Renal pain 26.03 18.30 16 14605 7743 90606083
Pituitary tumour removal 25.92 18.30 4 14617 10 90613816
Oophorectomy 25.90 18.30 8 14613 719 90613107
Blister 25.65 18.30 5 14616 254993 90358833
Injection site scar 25.34 18.30 9 14612 1248 90612578
Mobility decreased 25.04 18.30 5 14616 250729 90363097
Impaired healing 24.84 18.30 4 14617 234195 90379631
Swelling 24.57 18.30 19 14602 419039 90194787
Systemic lupus erythematosus 24.46 18.30 14 14607 361882 90251944
Diabetes mellitus 24.13 18.30 40 14581 64835 90548991
Dizziness 24.07 18.30 170 14451 589114 90024712
Pituitary tumour 23.97 18.30 8 14613 921 90612905
Pancreatic disorder 23.95 18.30 11 14610 2960 90610866
Irritable bowel syndrome 23.26 18.30 3 14618 207445 90406381
Drug interaction 22.90 18.30 8 14613 276445 90337381
Pancreatic neuroendocrine tumour 22.82 18.30 7 14614 615 90613211
Urticaria 22.75 18.30 11 14610 312723 90301103
Serum serotonin decreased 22.74 18.30 4 14617 27 90613799
Musculoskeletal stiffness 22.24 18.30 10 14611 296522 90317304
Adrenocortical insufficiency acute 22.13 18.30 10 14611 2591 90611235
Blood pressure increased 22.06 18.30 76 14545 197141 90416685
Hepatic pain 21.95 18.30 11 14610 3584 90610242
Biliary dilatation 21.74 18.30 10 14611 2701 90611125
Neoplasm 21.63 18.30 15 14606 8888 90604938
Muscle neoplasm 21.63 18.30 4 14617 37 90613789
Metastases to spine 21.53 18.30 11 14610 3732 90610094
Gallbladder neoplasm 21.44 18.30 4 14617 39 90613787
Carcinoid heart disease 21.26 18.30 4 14617 41 90613785
Spinal cord neoplasm 21.11 18.30 6 14615 404 90613422
Insulin-like growth factor decreased 21.08 18.30 6 14615 406 90613420
Blood glucose fluctuation 21.02 18.30 12 14609 5071 90608755
Haemangioma of liver 20.94 18.30 8 14613 1362 90612464
Product supply issue 20.80 18.30 10 14611 2982 90610844
Thyroid neoplasm 20.79 18.30 11 14610 4010 90609816
Lymphatic system neoplasm 20.76 18.30 4 14617 47 90613779
Postoperative adhesion 20.46 18.30 6 14615 452 90613374
Joint swelling 20.43 18.30 31 14590 503269 90110557
Pneumonia 20.00 18.30 46 14575 638013 89975813
Incorrect route of product administration 19.89 18.30 32 14589 50594 90563232
Toxic skin eruption 19.77 18.30 18 14603 15756 90598070
Metastases to bone 19.01 18.30 22 14599 25483 90588343
Optic nerve compression 18.80 18.30 3 14618 10 90613816
Spleen disorder 18.65 18.30 7 14614 1134 90612692
Body height increased 18.62 18.30 4 14617 83 90613743
Pancreatogenous diabetes 18.58 18.30 3 14618 11 90613815
Blood glucose abnormal 18.52 18.30 14 14607 9478 90604348
Injection site granuloma 18.49 18.30 4 14617 86 90613740
Meningioma 18.41 18.30 11 14610 5060 90608766
Blood gonadotrophin decreased 18.37 18.30 3 14618 12 90613814

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 205.12 22.04 373 9249 470812 42140901
Diarrhoea 191.86 22.04 358 9264 460491 42151222
Injection site pain 159.91 22.04 120 9502 57678 42554035
Inappropriate schedule of product administration 157.04 22.04 147 9475 95755 42515958
Off label use 142.55 22.04 387 9235 637948 41973765
Injection site mass 134.52 22.04 56 9566 8519 42603194
Neoplasm progression 129.59 22.04 81 9541 28919 42582794
Malignant neoplasm progression 124.11 22.04 137 9485 108263 42503450
Abdominal pain 121.70 22.04 180 9442 190291 42421422
Insulin-like growth factor increased 120.29 22.04 34 9588 1597 42610116
Flatulence 87.30 22.04 60 9562 25092 42586621
Cholelithiasis 79.39 22.04 55 9567 23291 42588422
Carcinoid heart disease 77.00 22.04 12 9610 20 42611693
Disease progression 76.53 22.04 125 9497 143531 42468182
Metastases to liver 71.37 22.04 45 9577 16281 42595432
Injection site haemorrhage 71.30 22.04 40 9582 11696 42600017
Pituitary tumour benign 61.02 22.04 18 9604 984 42610729
Carcinoid crisis 51.20 22.04 12 9610 264 42611449
Abdominal pain upper 49.60 22.04 76 9546 82533 42529180
Growth hormone deficiency 49.14 22.04 12 9610 316 42611397
Drug interaction 42.99 22.04 5 9617 266994 42344719
Flushing 42.60 22.04 47 9575 36981 42574732
Fatigue 38.01 22.04 196 9426 435445 42176268
Terminal state 37.99 22.04 19 9603 4404 42607309
Abdominal distension 36.20 22.04 61 9561 71674 42540039
Weight decreased 36.13 22.04 116 9506 207832 42403881
Pituitary tumour removal 34.63 22.04 5 9617 3 42611710
Treatment delayed 34.35 22.04 8 9614 171 42611542
Blood chromogranin A increased 34.28 22.04 9 9613 319 42611394
Incorrect route of product administration 33.55 22.04 34 9588 24271 42587442
Injection site nodule 33.49 22.04 14 9608 2147 42609566
Hypoglycaemia 31.67 22.04 52 9570 59802 42551911
Injection site abscess 31.64 22.04 11 9611 1021 42610692
Pancreatic neuroendocrine tumour metastatic 30.74 22.04 7 9615 135 42611578
Product dose omission issue 30.40 22.04 90 9532 154275 42457438
Insulin-like growth factor abnormal 30.31 22.04 5 9617 14 42611699
Palliative care 30.26 22.04 11 9611 1163 42610550
Injection site induration 30.01 22.04 15 9607 3472 42608241
Hepatic neoplasm 30.00 22.04 13 9609 2178 42609535
Steatorrhoea 29.86 22.04 10 9612 829 42610884
Bile duct stone 29.69 22.04 14 9608 2853 42608860
Asthenia 29.20 22.04 133 9489 280660 42331053
Malaise 28.73 22.04 109 9513 212047 42399666
Intestinal obstruction 28.71 22.04 33 9589 27125 42584588
Metastases to bone 28.67 22.04 25 9597 14784 42596929
Abdominal discomfort 27.86 22.04 56 9566 75199 42536514
Faeces pale 26.85 22.04 11 9611 1603 42610110
Carcinoid syndrome 26.48 22.04 6 9616 113 42611600
Hospitalisation 25.97 22.04 54 9568 74276 42537437
Product administered at inappropriate site 25.70 22.04 13 9609 3085 42608628
Acromegaly 24.92 22.04 5 9617 51 42611662
Eructation 23.66 22.04 15 9607 5471 42606242
Hepatic pain 23.58 22.04 10 9612 1590 42610123
Tumour necrosis 23.31 22.04 10 9612 1634 42610079
Biliary obstruction 22.35 22.04 12 9610 3217 42608496

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 322.42 17.54 680 20223 1138825 109429571
Inappropriate schedule of product administration 299.67 17.54 272 20631 203365 110365031
Malignant neoplasm progression 298.57 17.54 254 20649 174313 110394083
Injection site mass 268.49 17.54 118 20785 24495 110543901
Abdominal pain 247.64 17.54 387 20516 512602 110055794
Insulin-like growth factor increased 241.21 17.54 61 20842 2235 110566161
Death 229.94 17.54 445 20458 698424 109869972
Injection site pain 229.56 17.54 221 20682 177701 110390695
Flatulence 197.62 17.54 123 20780 52026 110516370
Off label use 190.68 17.54 667 20236 1499518 109068878
Neoplasm progression 157.63 17.54 116 20787 64479 110503917
Cholelithiasis 148.27 17.54 111 20792 63311 110505085
Metastases to liver 132.86 17.54 83 20820 35303 110533093
Abdominal distension 122.45 17.54 158 20745 174945 110393451
Weight decreased 106.22 17.54 257 20646 467800 110100596
Flushing 105.59 17.54 114 20789 104622 110463774
Disease progression 98.25 17.54 170 20733 243864 110324532
Intestinal obstruction 93.98 17.54 79 20824 53148 110515248
Asthenia 78.76 17.54 297 20606 688702 109879694
Hypoglycaemia 75.28 17.54 101 20802 116003 110452393
Faeces pale 74.92 17.54 27 20876 3330 110565066
Carcinoid heart disease 73.77 17.54 13 20890 74 110568322
Injection site nodule 73.32 17.54 29 20874 4617 110563779
Injection site haemorrhage 73.16 17.54 56 20847 32972 110535424
Blood growth hormone increased 67.56 17.54 19 20884 1049 110567347
Carcinoid crisis 64.55 17.54 16 20887 539 110567857
Terminal state 64.47 17.54 28 20875 5639 110562757
Insulin-like growth factor abnormal 64.30 17.54 11 20892 51 110568345
Carcinoid tumour pulmonary 63.57 17.54 15 20888 409 110567987
Product dose omission issue 61.76 17.54 166 20737 321616 110246780
Blood glucose increased 60.88 17.54 98 20805 132398 110435998
Hepatic neoplasm 60.54 17.54 24 20879 3843 110564553
Pituitary tumour benign 60.19 17.54 22 20881 2825 110565571
Drug hypersensitivity 58.99 17.54 8 20895 454082 110114314
Steatorrhoea 58.69 17.54 17 20886 1044 110567352
Rash 58.59 17.54 42 20861 820922 109747474
Metastases to bone 56.27 17.54 47 20856 31325 110537071
Drug interaction 55.91 17.54 13 20890 500170 110068226
Abdominal pain upper 55.23 17.54 168 20735 348943 110219453
Nausea 52.76 17.54 406 20497 1235284 109333112
Constipation 52.74 17.54 168 20735 357618 110210778
Pituitary tumour removal 52.50 17.54 8 20895 14 110568382
Injection site abscess 51.87 17.54 18 20885 1988 110566408
Growth hormone deficiency 51.72 17.54 13 20890 464 110567932
Blood chromogranin A increased 50.76 17.54 14 20889 719 110567677
Blood glucose decreased 50.46 17.54 43 20860 29445 110538951
Injection site discomfort 47.19 17.54 24 20879 6883 110561513
Abnormal faeces 45.98 17.54 26 20877 9210 110559186
Fatigue 45.09 17.54 387 20516 1215571 109352825
Rheumatoid arthritis 44.89 17.54 3 20900 299610 110268786
Product administered at inappropriate site 43.56 17.54 21 20882 5372 110563024
Pituitary tumour 43.35 17.54 14 20889 1239 110567157
Genitourinary tract neoplasm 43.03 17.54 8 20895 64 110568332
Decreased appetite 42.28 17.54 190 20713 475656 110092740
Carcinoid syndrome 41.88 17.54 10 20893 287 110568109
Tumour pain 41.56 17.54 17 20886 2950 110565446
Needle issue 41.16 17.54 31 20872 17809 110550587
Febrile neutropenia 40.14 17.54 6 20897 316761 110251635
Insulinoma 40.12 17.54 9 20894 195 110568201
Biliary obstruction 39.99 17.54 20 20883 5538 110562858
Vomiting 38.62 17.54 299 20604 910376 109658020
Arthropathy 37.48 17.54 5 20898 287517 110280879
Menopausal symptoms 37.34 17.54 15 20888 2486 110565910
Hepatic pain 37.09 17.54 18 20885 4672 110563724
Maternal exposure during pregnancy 36.90 17.54 3 20900 254880 110313516
Hospitalisation 36.30 17.54 82 20821 142411 110425985
Urticaria 36.18 17.54 8 20895 318849 110249547
Faeces discoloured 36.03 17.54 38 20865 33910 110534486
Intentional product use issue 35.66 17.54 3 20900 247903 110320493
Bile duct stone 34.86 17.54 19 20884 6270 110562126
Tumour necrosis 34.27 17.54 14 20889 2422 110565974
Neoplasm 34.21 17.54 23 20880 11064 110557332
Injection site induration 33.66 17.54 23 20880 11360 110557036
Sinusitis 32.56 17.54 8 20895 296680 110271716
Toxicity to various agents 32.41 17.54 26 20877 480529 110087867
Malaise 32.09 17.54 227 20676 671592 109896804
Palliative care 31.91 17.54 12 20891 1668 110566728
Pelvic neoplasm 31.57 17.54 8 20895 295 110568101
Acromegaly 31.50 17.54 7 20896 145 110568251
Glossodynia 31.08 17.54 3 20900 222001 110346395
Blood glucose abnormal 31.04 17.54 23 20880 12893 110555503
Salpingectomy 30.68 17.54 8 20895 331 110568065
Pericarditis 30.58 17.54 3 20900 219111 110349285
Hepatic lesion 29.56 17.54 19 20884 8474 110559922
Blister 29.52 17.54 4 20899 227372 110341024
Oophorectomy 29.51 17.54 8 20895 385 110568011
Hot flush 29.17 17.54 48 20855 65988 110502408
Incorrect route of product administration 28.88 17.54 47 20856 64014 110504382
Heart rate decreased 28.58 17.54 54 20849 82702 110485694
Hypersensitivity 28.33 17.54 21 20882 403977 110164419
Hand deformity 28.00 17.54 4 20899 218502 110349894
Metastases to lymph nodes 27.95 17.54 23 20880 15009 110553387
Metastases to spinal cord 27.90 17.54 7 20896 248 110568148
C-reactive protein increased 27.90 17.54 4 20899 217915 110350481
Pancreatic disorder 27.84 17.54 14 20889 3920 110564476
Stomatitis haemorrhagic 27.71 17.54 7 20896 255 110568141
Pneumonia 27.63 17.54 80 20823 876634 109691762
Treatment failure 27.59 17.54 9 20894 277225 110291171
Drug intolerance 27.40 17.54 22 20881 406490 110161906
Eructation 27.17 17.54 22 20881 14035 110554361
Injection site pruritus 26.43 17.54 40 20863 51218 110517178
Haemangioma of liver 26.38 17.54 10 20893 1420 110566976
Liver abscess 26.17 17.54 17 20886 7722 110560674
Bronchiolitis 26.10 17.54 15 20888 5478 110562918
Therapeutic product effect decreased 26.01 17.54 7 20896 244309 110324087
Insulin-like growth factor decreased 26.00 17.54 8 20895 605 110567791
Blood pressure increased 25.84 17.54 107 20796 258266 110310130
Cholecystitis 25.75 17.54 28 20875 25854 110542542
Dizziness 25.11 17.54 221 20682 697972 109870424
Serum serotonin increased 25.09 17.54 7 20896 375 110568021
Injection site scar 24.81 17.54 9 20894 1131 110567265
Faeces soft 24.80 17.54 19 20884 11191 110557205
Musculoskeletal stiffness 24.66 17.54 11 20892 279811 110288585
Ascites 24.29 17.54 54 20849 92754 110475642
Thyroid neoplasm 24.11 17.54 12 20891 3289 110565107
Helicobacter infection 24.09 17.54 3 20900 181874 110386522
Gastroenteropancreatic neuroendocrine tumour disease 24.02 17.54 5 20898 75 110568321
Gallbladder neoplasm 23.49 17.54 5 20898 84 110568312
Metastases to abdominal cavity 23.17 17.54 8 20895 870 110567526
Hyperglycaemia 22.82 17.54 50 20853 85040 110483356
Pancreatic neuroendocrine tumour 22.78 17.54 8 20895 915 110567481
Renal pain 22.52 17.54 17 20886 9800 110558596
Gastrointestinal neoplasm 22.47 17.54 7 20896 551 110567845
Hepatic embolisation 22.11 17.54 4 20899 27 110568369
Pancreatic failure 21.57 17.54 10 20893 2344 110566052
Metastases to spine 21.23 17.54 13 20890 5330 110563066
Syncope 21.14 17.54 85 20818 202451 110365945
Injection site hypoaesthesia 21.00 17.54 7 20896 684 110567712
Lack of injection site rotation 20.96 17.54 8 20895 1158 110567238
Diabetes mellitus 20.79 17.54 53 20850 99328 110469068
Biliary colic 20.38 17.54 12 20891 4585 110563811
Impaired healing 20.26 17.54 6 20897 196711 110371685
Headache 20.24 17.54 255 20648 882122 109686274
Cholecystitis infective 20.05 17.54 11 20892 3676 110564720
Wound 19.45 17.54 10 20893 234427 110333969
Muscle neoplasm 19.34 17.54 4 20899 58 110568338
Hepatomegaly 19.30 17.54 22 20881 21392 110547004
Glycosylated haemoglobin increased 19.18 17.54 23 20880 23596 110544800
Pruritus 19.08 17.54 52 20851 581508 109986888
Hyperhidrosis 19.06 17.54 78 20825 187220 110381176
Neutropenia 18.81 17.54 26 20877 374594 110193802
Spinal cord neoplasm 18.45 17.54 6 20897 543 110567853
Hormone level abnormal 18.42 17.54 9 20894 2371 110566025
Lymphatic system neoplasm 18.38 17.54 4 20899 75 110568321
Postoperative adhesion 18.12 17.54 6 20897 575 110567821
Meningioma 18.07 17.54 12 20891 5653 110562743
Hepatobiliary disease 18.06 17.54 7 20896 1055 110567341
Swelling 17.99 17.54 24 20879 351017 110217379
Carcinoid tumour 17.98 17.54 6 20897 589 110567807
Overdose 17.92 17.54 11 20892 233783 110334613
Hyperadrenocorticism 17.90 17.54 6 20897 597 110567799
Acute kidney injury 17.86 17.54 61 20842 635369 109933027

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC H01CB03 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
HYPOTHALAMIC HORMONES
Somatostatin and analogues
FDA MoA N0000000194 Somatostatin Receptor Agonists
MeSH PA D000970 Antineoplastic Agents
FDA EPC N0000175904 Somatostatin Analog
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

H01CB Somatostatin and analogues 4 drugs
octreotidepaltusotinepasireotidesomatostatin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acromegaly indication 74107003 DOID:2449
Hypersomatotropic gigantism indication 86073008
Thyroid-stimulating hormone secreting pituitary tumour indication 127024001 DOID:1785
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of gallbladder contraindication 39621005 DOID:0060262
Hypothyroidism contraindication 40930008 DOID:1459
Bradycardia contraindication 48867003
Hyperglycemia contraindication 80394007 DOID:4195
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409
Hypoglycemic disorder contraindication 237630007
Calculus in biliary tract contraindication 266474003




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.65 acidic
pKa2 12.16 acidic
pKa3 12.71 acidic
pKa4 13.18 acidic
pKa5 13.43 acidic
pKa6 13.67 acidic
pKa7 10.31 Basic
pKa8 6.97 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Somatostatin receptor type 2 GPCR AGONIST Ki 9.60 IUPHAR CHEMBL
Somatostatin receptor type 5 GPCR AGONIST Ki 9.30 IUPHAR CHEMBL
Somatostatin receptor type 3 GPCR AGONIST Ki 8 IUPHAR
Somatostatin receptor type 4 GPCR Ki 7.18 PDSP
Somatostatin receptor type 1 GPCR Ki 6.30 PDSP
Somatostatin receptor type 3 GPCR AGONIST Ki 6.90 IUPHAR
Somatostatin receptor type 2 GPCR AGONIST Ki 9.10 IUPHAR
Somatostatin receptor type 3 GPCR AGONIST IC50 8.20 IUPHAR
Somatostatin receptor type 5 GPCR AGONIST Ki 7.60 IUPHAR
Somatostatin receptor type 2 GPCR AGONIST Ki 8.80 IUPHAR

External reference:

IDSource
4026631 VUID
N0000179366 NUI
D04666 KEGG_DRUG
127984-74-1 SECONDARY_CAS_RN
4026631 VANDF
C0209211 UMLSCUI
CHEMBL1201185 ChEMBL_ID
CHEMBL1201184 ChEMBL_ID
DB06791 DRUGBANK_ID
C060347 MESH_SUPPLEMENTAL_RECORD_UI
2031 IUPHAR_LIGAND_ID
6649 INN_ID
0G3DE8943Y UNII
6918011 PUBCHEM_CID
236167 RXNORM
18121 MMSL
354365 MMSL
d04961 MMSL
005272 NDDF
005273 NDDF
327379003 SNOMEDCT_US
395765000 SNOMEDCT_US
429611006 SNOMEDCT_US
CHEBI:135901 CHEBI
0G3DE8943Y INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
SOMATULINE DEPOT HUMAN PRESCRIPTION DRUG LABEL 1 15054-1060 INJECTION 60 mg SUBCUTANEOUS NDA 29 sections
SOMATULINE DEPOT HUMAN PRESCRIPTION DRUG LABEL 1 15054-1090 INJECTION 90 mg SUBCUTANEOUS NDA 29 sections
SOMATULINE DEPOT HUMAN PRESCRIPTION DRUG LABEL 1 15054-1120 INJECTION 120 mg SUBCUTANEOUS NDA 29 sections
Lanreotide Acetate HUMAN PRESCRIPTION DRUG LABEL 1 69097-870 INJECTION 120 mg SUBCUTANEOUS NDA 29 sections
Lanreotide Acetate HUMAN PRESCRIPTION DRUG LABEL 1 69097-880 INJECTION 60 mg SUBCUTANEOUS NDA 29 sections
Lanreotide Acetate HUMAN PRESCRIPTION DRUG LABEL 1 69097-890 INJECTION 90 mg SUBCUTANEOUS NDA 29 sections
LANREOTIDE ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 69097-906 INJECTION 120 mg SUBCUTANEOUS ANDA 33 sections
LANREOTIDE ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 69097-907 INJECTION 60 mg SUBCUTANEOUS ANDA 33 sections
LANREOTIDE ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 69097-908 INJECTION 90 mg SUBCUTANEOUS ANDA 33 sections
LANREOTIDE ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 76282-718 INJECTION 60 mg SUBCUTANEOUS ANDA 32 sections
LANREOTIDE ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 76282-719 INJECTION 90 mg SUBCUTANEOUS ANDA 32 sections
LANREOTIDE ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 76282-720 INJECTION 120 mg SUBCUTANEOUS ANDA 32 sections